Downregulation Of Nlrp12 Enhances The Proliferation, Migration And Drug-Resistance Of Colorectal Cancer Cells By Modulating Mek/Erk/Gli1 Signaling Pathway

Guofeng Pan,Xinguo Zhu,Yizhou Yao,Hui Zhang,Shenghua Zhan,Liang Sun,Xiaodong Yang,Daiwei Wan,Zheng Zhu,Zhengwu Cheng,Peirao Li,Songbing He
2018-01-01
Abstract:Objective: To investigate the role of inflammasome NLRP12 in the tumorigenesis of colorectal cancer and drug-resistance properties of colorectal cancer cell lines. Methods: NLRP12 protein expression in 57 CRC tissue specimens and surrounding normal tissues were investigated by immunohistochemical analysis. Western blotting and quantitative real-time polymerase chain reaction (QRT-PCR) were used to detect the protein and mRNA expression of NLRP12 in CRC tissues and cells. Later NLRP12 siRNA was transfected into HCT116 cells to explore the effects of NLRP12 on the proliferation, migration and drug-resistance in colorectal cancer cells in vitro. Results: NLRP12 protein levels were decreased in CRC tissues compared to surrounding normal tissues. This decrement in NLRP12 protein levels in CRC tissues was significantly associated with tumor size, Dukes stages, and TNM stages of CRC patients (P<0.05). Furthermore, downregulation of NLRP12 in HCT116 cells promoted cells growth and migration (P<0.05). And these HCT116 cells were shown to be more resistant to cisplatin (P<0.05). NLRP12 negatively regulated the expression of phosphorylation-extracellular signal-regulated kinase (p-ERK) and GLI1 in HCT116 cells, and restraining mitogen-activated protein kinases (MAPK) pathway by using the mitogen-activated extracellular kinases (MEK) inhibitor U0126 blocked the effect of NLRP12 on GLI1. Conclusion: Our preliminary results confirm that NLRP12 may play an important role in the tumorigenesis and drug-resistance of colorectal cancer. Thus, NLRP12 may be a potential marker to treat colorectal cancers.
What problem does this paper attempt to address?